What is the current Opthea market capitalization?
The current market capitalization of Opthea is 344.19 M USD.
Opthea Market capitalization 2024
Opthea Market capitalization
344.19 M USD
Ticker
OPT.AX
ISIN
AU000000OPT2
WKN
A2AB8J
In 2024, Opthea's market cap stood at 344.19 M USD, a 102.75% increase from the 169.76 M USD market cap in the previous year.
The Opthea Market capitalization history
| YEAR | Market Capitalization (undefined USD) |
|---|---|
| 2024 | 344.19 |
| 2023 | 298.53 |
| 2022 | 441.73 |
| 2021 | 535.95 |
| 2020 | 679.41 |
| 2019 | 397.8 |
| 2018 | 114.24 |
| 2017 | 130.27 |
| 2016 | 83.03 |
| 2015 | 22.18 |
| 2014 | 9.45 |
| 2013 | 12.81 |
| 2012 | 20.18 |
| 2011 | 27.4 |
| 2010 | 28.75 |
| 2009 | 32.21 |
| 2008 | 35.05 |
| 2007 | 55.01 |
| 2006 | 49.52 |
| 2005 | 57.59 |
Opthea Aktienanalyse
What does Opthea do?
Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea ist eines der beliebtesten Unternehmen auf Eulerpool.com.Market capitalization Details
Exploring Opthea's Market Capitalization
Opthea's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.
Year-to-Year Comparison
A yearly comparison of Opthea's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.
Impact on Investments
Opthea's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.
Interpreting Market Capitalization Fluctuations
Variations in Opthea’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.
Frequently Asked Questions about Opthea stock
What is market capitalization?
The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Opthea.
How has the market capitalization of Opthea developed in recent years?
The market capitalization of Opthea has increased/decreased by 102.75% compared to the previous year.
What does market capitalization mean for investors?
The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.
Why is market capitalization an important indicator for investors?
The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.
Why does the market capitalization fluctuate?
The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.
What role does market capitalization play in the valuation of Opthea?
In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.
Does the market capitalization influence the performance of Opthea?
There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Does the market capitalization of Opthea have an influence on indices?
Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).
How much dividend does Opthea pay?
Over the past 12 months, Opthea paid a dividend of 0.15 USD . This corresponds to a dividend yield of about 27.18 %. For the coming 12 months, Opthea is expected to pay a dividend of 0 USD.
What is the dividend yield of Opthea?
The current dividend yield of Opthea is 27.18 %.
When does Opthea pay dividends?
Opthea pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Opthea?
Opthea paid dividends every year for the past 4 years.
What is the dividend of Opthea?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Opthea located?
Opthea is assigned to the 'Health' sector.
Wann musste ich die Aktien von Opthea kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Opthea from 2/24/2005 amounting to 0.15 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2005.
When did Opthea pay the last dividend?
The last dividend was paid out on 2/24/2005.
What was the dividend of Opthea in the year 2023?
In the year 2023, Opthea distributed 0 USD as dividends.
In which currency does Opthea pay out the dividend?
The dividends of Opthea are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Opthea
Our stock analysis for Opthea Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Opthea Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
